Raymond James analyst Michael Rose maintains Triumph Bancorp (NASDAQ:TBK) with a Outperform and lowers the price target from $79 to $68.
ARS Pharma Announces Topline Results From Repeat Dosing Study Of neffy Under Nasal Allergen Challenge Conditions, Readies Data For Response To FDA’s Complete Response Letter
Repeat doses of neffy under nasal allergen challenge demonstrate a pharmacokinetic profile greater than or similar to injection, and a pharmacodynamic profile greater than injection Company believes completion of
